-
1
-
-
47949120118
-
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
-
Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1012-1018. doi: 10.1002/ibd.20377
-
(2008)
Inflamm Bowel Dis
, vol.14
, pp. 1012-1018
-
-
Schultz, M.1
-
2
-
-
3843116530
-
Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917
-
Grozdanov L, Raasch C, Schultz J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004; 186: 5432-5441. doi: 10.1128/JB.186.16.5432-5441.2004
-
(2004)
J Bacteriol
, vol.186
, pp. 5432-5441
-
-
Grozdanov, L.1
Raasch, C.2
Schultz, J.3
-
3
-
-
34248399194
-
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin
-
Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007; 75: 2399-2407. doi: 10.1128/IAI.01563-06
-
(2007)
Infect Immun
, vol.75
, pp. 2399-2407
-
-
Schlee, M.1
Wehkamp, J.2
Altenhoefer, A.3
Oelschlaeger, T.A.4
Stange, E.F.5
Fellermann, K.6
-
4
-
-
0029129487
-
Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets
-
Mestecky J, ed. New York: Plenum Press
-
Mandel L, Trebichavsky I, Splichal I, et al. Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets. In: Mestecky J, ed. Advances in Mucosal Immunology. New York: Plenum Press; 1995: 463-464.
-
(1995)
Advances in Mucosal Immunology.
, pp. 463-464
-
-
Mandel, L.1
Trebichavsky, I.2
Splichal, I.3
-
5
-
-
4644228771
-
Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats
-
Lorenz A, Schulze J. Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats. Microecol Ther 1996; 24: 45-51.
-
(1996)
Microecol Ther
, vol.24
, pp. 45-51
-
-
Lorenz, A.1
Schulze, J.2
-
6
-
-
1642374075
-
The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cels by different enteroinvasive bacterial pathogens
-
Altenhoefer A, Oswald S, Sonnenborn U, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cels by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 2004; 40: 223-229. doi: 10.1016/S0928- 8244(03)00368-7
-
(2004)
FEMS Immunol Med Microbiol
, vol.40
, pp. 223-229
-
-
Altenhoefer, A.1
Oswald, S.2
Sonnenborn, U.3
-
7
-
-
33846894974
-
Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair
-
Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9: 804-816. doi: 10.1111/j.1462-5822.2006.00836.x
-
(2007)
Cell Microbiol
, vol.9
, pp. 804-816
-
-
Zyrek, A.A.1
Cichon, C.2
Helms, S.3
Enders, C.4
Sonnenborn, U.5
Schmidt, M.A.6
-
8
-
-
33750622338
-
Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917
-
Valdebenito M, Crumbliss AL, Winkelmann G, Hantke K. Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int J Med Microbiol 2006; 296: 513-520. doi: 10.1016/j. ijmm.2006.06.003
-
(2006)
Int J Med Microbiol
, vol.296
, pp. 513-520
-
-
Valdebenito, M.1
Crumbliss, A.L.2
Winkelmann, G.3
Hantke, K.4
-
9
-
-
20144365358
-
Escherichia coli Nissle 1917 distinctively modulates T cell cycling and expansion via toll-like receptor 2 signaling
-
Sturm A, Rilling K, Baumgart DC, et al. Escherichia coli Nissle 1917 distinctively modulates T cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005; 73: 1452-1465. doi: 10.1128/ IAI.73.3.1452-1465.2005
-
(2005)
Infect Immun
, vol.73
, pp. 1452-1465
-
-
Sturm, A.1
Rilling, K.2
Baumgart, D.C.3
-
10
-
-
33750239826
-
Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells
-
Helwig U, Lammers KM, Rizzello F, et al. Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 2006; 12: 5978-5986. doi: 10.3748/wjg.v12.i37.5978
-
(2006)
World J Gastroenterol
, vol.12
, pp. 5978-5986
-
-
Helwig, U.1
Lammers, K.M.2
Rizzello, F.3
-
11
-
-
33748662190
-
Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): Results of a prospective study of the records of 3,807 patients
-
Krammer HJ, Kämper H, von Bünau R, et al. Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients. Z Gastroenterol 2006; 44: 651-656. doi: 10.1055/s-2006-926909
-
(2006)
Z Gastroenterol
, vol.44
, pp. 651-656
-
-
Krammer, H.J.1
Kämper, H.2
von Bünau, R.3
-
12
-
-
34248136340
-
Inflammatory bowel disease: Clinical aspects and established and evolving therapies
-
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641- 1657. doi: 10.1016/S0140-6736(07)60751-X
-
(2007)
Lancet
, vol.369
, pp. 1641-1657
-
-
Baumgart, D.C.1
Sandborn, W.J.2
-
14
-
-
1542435317
-
Genetic and pathogenetic insights into inflammatory bowel disease
-
Pallone F, Blanco Gdel V, Vavassori P, Monteleone I, Fina D, Monteleone G. Genetic and pathogenetic insights into inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5: 487-492.
-
(2003)
Curr Gastroenterol Rep
, vol.5
, pp. 487-492
-
-
Pallone, F.1
Blanco Gdel, V.2
Vavassori, P.3
Monteleone, I.4
Fina, D.5
Monteleone, G.6
-
15
-
-
84923087600
-
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?
-
Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014; 5: 550-559. doi: 10.4291/wjgp.v5.i4.550
-
(2014)
World J Gastrointest Pathophysiol
, vol.5
, pp. 550-559
-
-
Bringiotti, R.1
Ierardi, E.2
Lovero, R.3
Losurdo, G.4
Di Leo, A.5
Principi, M.6
-
17
-
-
84904765781
-
Therapeutic modulation of gut microbiota: Current clinical applications and future perspectives
-
Ianiro G, Bibbò S, Gasbarrini A, Cammarota G. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr Drug Targets 2014; 15: 762-770. doi: 10.2174/1389450115666140606111402
-
(2014)
Curr Drug Targets
, vol.15
, pp. 762-770
-
-
Ianiro, G.1
Bibbò, S.2
Gasbarrini, A.3
Cammarota, G.4
-
18
-
-
84916229815
-
Fecal microbiota transplantation in inflammatory bowel disease: Beyond the excitement
-
Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) 2014; 93: e97. doi: 10.1097/ MD.0000000000000097
-
(2014)
Medicine (Baltimore)
, vol.93
-
-
Ianiro, G.1
Bibbò, S.2
Scaldaferri, F.3
Gasbarrini, A.4
Cammarota, G.5
-
19
-
-
84925595618
-
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
-
Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 2015; 149: 191-212. doi: 10.1016/j.pharmthera.2014.12.006
-
(2015)
Pharmacol Ther
, vol.149
, pp. 191-212
-
-
Cammarota, G.1
Ianiro, G.2
Cianci, R.3
Bibbò, S.4
Gasbarrini, A.5
Currò, D.6
-
20
-
-
84907578280
-
Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: Is there an involvement of microbiota?
-
Montenegro L, Losurdo G, Licinio R, et al. Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? Curr Drug Saf 2014; 9: 196-204. doi: 10.2174/1574886309666140424143852
-
(2014)
Curr Drug Saf
, vol.9
, pp. 196-204
-
-
Montenegro, L.1
Losurdo, G.2
Licinio, R.3
-
21
-
-
68049137869
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration
-
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100. doi: 10.1371/journal.pmed.1000100
-
(2009)
PLoS Med
, vol.6
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
-
23
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
-
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. doi: 10.1016/0197-2456(95)00134-4
-
(1996)
Control Clin Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
-
24
-
-
0030611915
-
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
-
Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858. doi: 10.1046/j.1365-2036.1997.00225.x
-
(1997)
Aliment Pharmacol Ther
, vol.11
, pp. 853-858
-
-
Kruis, W.1
Schütz, E.2
Fric, P.3
Fixa, B.4
Judmaier, G.5
Stolte, M.6
-
25
-
-
4644239296
-
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
-
Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623. doi: 10.1136/ gut.2003.037747
-
(2004)
Gut
, vol.53
, pp. 1617-1623
-
-
Kruis, W.1
Fric, P.2
Pokrotnieks, J.3
-
26
-
-
77950797408
-
Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)
-
Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13. doi: 10.1186/1472-6882-10-13
-
(2010)
BMC Complement Altern Med
, vol.10
, pp. 13
-
-
Matthes, H.1
Krummenerl, T.2
Giensch, M.3
Wolff, C.4
Schulze, J.5
-
27
-
-
84927799957
-
Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial
-
Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard- Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014; 8: 1498-1505. doi: 10.1016/j.crohns.2014.06.001
-
(2014)
J Crohns Colitis
, vol.8
, pp. 1498-1505
-
-
Petersen, A.M.1
Mirsepasi, H.2
Halkjær, S.I.3
Mortensen, E.M.4
Nordgaard-Lassen, I.5
Krogfelt, K.A.6
-
28
-
-
0033592203
-
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
-
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639. doi: 10.1016/S0140-6736(98)06343-0
-
(1999)
Lancet
, vol.354
, pp. 635-639
-
-
Rembacken, B.J.1
Snelling, A.M.2
Hawkey, P.M.3
Chalmers, D.M.4
Axon, A.T.5
-
29
-
-
54049093308
-
Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: An open-label pilot study
-
Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008; 46: 874-875. doi: 10.1055/s- 2008-1027463
-
(2008)
Z Gastroenterol
, vol.46
, pp. 874-875
-
-
Henker, J.1
Müller, S.2
Laass, M.W.3
Schreiner, A.4
Schulze, J.5
-
30
-
-
84930475582
-
Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease
-
Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7: 473-487. doi: 10.2147/CEG.S27530
-
(2014)
Clin Exp Gastroenterol
, vol.7
, pp. 473-487
-
-
Ghouri, Y.A.1
Richards, D.M.2
Rahimi, E.F.3
Krill, J.T.4
Jelinek, K.A.5
DuPont, A.W.6
-
31
-
-
84869089859
-
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management
-
Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030. doi: 10.1016/j. crohns.2012.09.002
-
(2012)
J Crohns Colitis
, vol.6
, pp. 991-1030
-
-
Dignass, A.1
Lindsay, J.O.2
Sturm, A.3
-
32
-
-
0037309595
-
Randomized controlled trial of the effect of bifidobacteria fermented milk on ulcerative colitis
-
Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
-
(2003)
J Am Coll Nutr
, vol.22
, pp. 56-63
-
-
Ishikawa, H.1
Akedo, I.2
Umesaki, Y.3
Tanaka, R.4
Imaoka, A.5
Otani, T.6
-
33
-
-
33646560334
-
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
-
Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574. doi: 10.1111/j.1365-2036.2006.02927.x
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 1567-1574
-
-
Zocco, M.A.1
dal Verme, L.Z.2
Cremonini, F.3
-
34
-
-
59749088586
-
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis
-
Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443. doi: 10.1038/ajg.2008.118
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 437-443
-
-
Miele, E.1
Pascarella, F.2
Giannetti, E.3
Quaglietta, L.4
Baldassano, R.N.5
Staiano, A.6
-
35
-
-
37249053411
-
High-dose probiotics for the treatment of active pouchitis
-
Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-2084. doi: 10.1007/s10350-007-9068-4
-
(2007)
Dis Colon Rectum
, vol.50
, pp. 2075-2084
-
-
Gionchetti, P.1
Rizzello, F.2
Morselli, C.3
-
36
-
-
26944448942
-
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice
-
Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22: 721-728. doi: 10.1111/j.1365-2036.2005.02642.x
-
(2005)
Aliment Pharmacol Ther
, vol.22
, pp. 721-728
-
-
Shen, B.1
Brzezinski, A.2
Fazio, V.W.3
|